Logo image of TELO.CA

TELO GENOMICS CORP (TELO.CA) Stock Fundamental Analysis

Canada - TSX-V:TELO - CA87975M2085 - Common Stock

0.075 CAD
0 (0%)
Last: 11/17/2025, 7:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TELO. TELO was compared to 21 industry peers in the Biotechnology industry. TELO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TELO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TELO had negative earnings in the past year.
In the past year TELO has reported a negative cash flow from operations.
In the past 5 years TELO always reported negative net income.
In the past 5 years TELO always reported negative operating cash flow.
TELO.CA Yearly Net Income VS EBIT VS OCF VS FCFTELO.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M

1.2 Ratios

TELO's Return On Assets of -298.34% is on the low side compared to the rest of the industry. TELO is outperformed by 66.67% of its industry peers.
TELO has a Return On Equity (-527.92%) which is in line with its industry peers.
Industry RankSector Rank
ROA -298.34%
ROE -527.92%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TELO.CA Yearly ROA, ROE, ROICTELO.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K -1K

1.3 Margins

TELO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TELO.CA Yearly Profit, Operating, Gross MarginsTELO.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 5 years ago, TELO has more shares outstanding
TELO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TELO.CA Yearly Shares OutstandingTELO.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2025 20M 40M 60M 80M 100M
TELO.CA Yearly Total Debt VS Total AssetsTELO.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2025 1M 2M 3M

2.2 Solvency

Based on the Altman-Z score of -44.66, we must say that TELO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -44.66, TELO is not doing good in the industry: 61.90% of the companies in the same industry are doing better.
TELO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -44.66
ROIC/WACCN/A
WACCN/A
TELO.CA Yearly LT Debt VS Equity VS FCFTELO.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2M -2M -4M -6M -8M

2.3 Liquidity

TELO has a Current Ratio of 2.25. This indicates that TELO is financially healthy and has no problem in meeting its short term obligations.
TELO has a better Current ratio (2.25) than 61.90% of its industry peers.
TELO has a Quick Ratio of 2.25. This indicates that TELO is financially healthy and has no problem in meeting its short term obligations.
TELO has a better Quick ratio (2.25) than 61.90% of its industry peers.
Industry RankSector Rank
Current Ratio 2.25
Quick Ratio 2.25
TELO.CA Yearly Current Assets VS Current LiabilitesTELO.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2025 1M 2M 3M

More info and screens

0

3. Growth

3.1 Past

TELO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.68%, which is quite good.
EPS 1Y (TTM)18.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TELO. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TELO.CA Price Earnings VS Forward Price EarningsTELO.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TELO.CA Per share dataTELO.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.01 -0.02

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TELO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TELO GENOMICS CORP

TSX-V:TELO (11/17/2025, 7:00:00 PM)

0.075

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04
Earnings (Next)11-20 2025-11-20
Inst Owners0.34%
Inst Owner ChangeN/A
Ins Owners4.04%
Ins Owner ChangeN/A
Market Cap7.53M
Revenue(TTM)N/A
Net Income(TTM)-2.72M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 14.63
P/tB 14.63
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -298.34%
ROE -527.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.25
Quick Ratio 2.25
Altman-Z -44.66
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)81.48%
Cap/Depr(5y)60.72%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.48%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y5.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.31%
OCF growth 3YN/A
OCF growth 5YN/A

TELO GENOMICS CORP / TELO.CA FAQ

Can you provide the ChartMill fundamental rating for TELO GENOMICS CORP?

ChartMill assigns a fundamental rating of 2 / 10 to TELO.CA.


What is the valuation status for TELO stock?

ChartMill assigns a valuation rating of 0 / 10 to TELO GENOMICS CORP (TELO.CA). This can be considered as Overvalued.


What is the profitability of TELO stock?

TELO GENOMICS CORP (TELO.CA) has a profitability rating of 0 / 10.